

PRODUCT INFORMATION




Nipecotic Acid

Item No. 36126

CAS Registry No.: 498-95-3
Formal Name: 3-piperidinecarboxylic acid
Synonyms: (±)-Nipecotic Acid, (R,S)-Nipecotic Acid, 3-Piperidine Carboxylic Acid, DL-Piperidine 3-Carboxylic Acid

MF: C₆H₁₁NO₂
FW: 129.2
Purity: ≥95%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Nipecotic acid is supplied as a solid. A stock solution may be made by dissolving the nipecotic acid in the solvent of choice, which should be purged with an inert gas. Nipecotic acid is slightly soluble in ethanol, DMSO, and dimethyl formamide.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of nipecotic acid can be prepared by directly dissolving the solid in aqueous buffers. The solubility of nipecotic acid in PBS (pH 7.2) is approximately 10 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Nipecotic acid is an inhibitor of GABA transporters (GAT; IC₅₀s = 2.6, 310, 29, and 16 μM for mouse GAT-1, GAT-2, GAT-3, and GAT-4, respectively).¹ It does not bind GABA_A or GABA_B receptors (IC₅₀s = >100 μM for both) but does bind the adenosine A₃ receptor (IC₅₀ = 0.01 μM).^{2,3} Nipecotic acid inhibits GABA uptake in isolated rabbit choroid plexus (IC₅₀ = 244 μM).⁴ It inhibits lactate dehydrogenase (LDH) release (EC₅₀ = ~5 μM) and aggregation of a mutant form of huntingtin, htt-N63-148Q, in PC12 cells.⁵ Intraventricular administration of nipecotic acid (300 μg/animal) decreases tail flick reaction time in a rat model of morphine-induced analgesia.⁶

References

1. Kragler, A., Höfner, G., and Wanner, K.T. Novel parent structures for inhibitors of the murine GABA transporters mGAT3 and mGAT4. *Eur. J. Pharmacol.* **519(1-2)**, 43-47 (2005).
2. Bowery, N.G., Hill, D.R., and Hudson, A.L. Characteristics of GABAB receptor binding sites on rat whole brain synaptic membranes. *Br. J. Pharmacol.* **78(1)**, 191-206 (1983).
3. Minetti, P., Tinti, M.O., Carminati, P., et al. 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A_{2A} adenosine receptor antagonists. Design, synthesis, and pharmacological characterization. *J. Med. Chem.* **48(22)**, 6887-6896 (2005).
4. Ramanathan, V.K., Brett, C.M., and Giacomini, K.M. Na⁺-dependent γ-aminobutyric acid (GABA) transport in the choroid plexus of rabbit. *Biochim. Biophys. Acta* **1330(1)**, 94-102 (1997).
5. Wang, W., Duan, W., Igarashi, S., et al. Compounds blocking mutant huntingtin toxicity identified using a Huntington's disease neuronal cell model. *Neurobiol. Dis.* **20(2)**, 500-508 (2005).
6. Mantegazza, P., Tammiso, R., Vicentini, L., et al. Nipecotic acid and guvacine antagonism on morphine analgesia in rats. *Pharmacol. Res. Commun.* **11(8)**, 657-662 (1979).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/19/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM